Impact of neoadjuvant therapy on angioplastic lobectomy: a retrospective study
Neoadjuvant therapy does not adversely affect morbidity, arterial repair complications or mortality in AL. There are no survival differences at 5 years. AL remains a safe option following NT.
Authors
- Adeline Morisot (ORCID: https://orcid.org/0000-0003-0906-2200)
- Jean‐Phillippe Berthet
- Abel Gómez-Caro
- Quentin Rudondy
- Kheira Hireche (ORCID: https://orcid.org/0000-0002-4269-2282)
- Florent Alcaraz
- Sébastien Frey (ORCID: https://orcid.org/0000-0001-5585-7245)
- Aude Nguyen (ORCID: https://orcid.org/0000-0003-4425-6676)
- Charlotte Cohen (ORCID: https://orcid.org/0009-0008-3519-4227)
- Mauro Guarino
- Tayeb Benkiran
Institutions
- Institut de Chimie de Nice (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Hôpital l'Archet (FR)
- Observatoire de la Côte d’Azur (FR)
- Hôpital Pasteur (FR)
- Cognition Behaviour Technology (FR)
- Hôpital Arnaud de Villeneuve (FR)
Publication Details
- Journal
- Interdisciplinary CardioVascular and Thoracic Surgery
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1093/icvts/ivae191
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00